AstraZeneca: Leukemia, Lymphocytic, Chronic, B-Cell trials
The registry lists 42 Leukemia, Lymphocytic, Chronic, B-Cell studies with AstraZeneca as lead sponsor. 6 are open to participants now and 17 have results posted.
Phase 1 16Phase 2 15Phase 3 7Phase 4 1No phase 13(a study in two phases counts in both)
Studies
Open to participants first, then studies with results posted, then the rest; newest registration first within each.
- Observ Prosp Study of Acalabrutinib in CLL Therapy in Real Clinical Practice in BelarusRecruitingNCT07288515
- MAVRiC Studies 2L Treatment With AV in Patients With CLL/SLL Who Have Relapsed After a Course of BTKi + BCL2i Combination, With or Without ObinutuzumabRecruitingNCT07024706Phase 2
- A Study of AZD0486 Monotherapy or in Combination With Other Anti-Cancer Agents for Mature B-Cell MalignanciesRecruitingNCT06564038Phase 1/2
- AQUALIS:QoL of CLL Patients Treated With Acalabrutinib in France, Retrospective Study Based on Data From PLATON DatabaseRecruitingNCT06548152
- A Study to Evaluate Safety, PK, PD and Efficacy of AZD5492, a T Cell-engaging Antibody Targeting CD20 in Subjects With R/R B-Cell Malignancies.RecruitingNCT06542250Phase 1/2
- PICAROS - Acalabrutinib RWE on 1L CLL in SpainRecruitingNCT05999877
- Acalabrutinib Study in Indian Patients With Chronic Lymphocytic Leukaemia & Relapsed and Refractory Mantle Cell LymphomaCompletedNCT04930536Phase 4Results posted
- Study of Acalabrutinib Versus Chlorambucil Plus Rituximab in Adult Subjects With Previously Untreated Chronic Lymphocytic LeukemiaActive, not recruitingNCT04075292Phase 3Results posted
- Acalabrutinib Safety Study in Untreated and Relapsed or Refractory Chronic Lymphocytic Leukemia PatientsCompletedNCT04008706Phase 3Results posted
- Study of Acalabrutinib in Chinese Adult Subjects With Relapsed or Refractory Mantle Cell Lymphoma, Chronic Lymphocytic Leukemia or Other B-cell MalignanciesActive, not recruitingNCT03932331Phase 1/2Results posted
- A Study of Acalabrutinib vs Investigator's Choice of Idelalisib Plus Rituximab or Bendamustine Plus Rituximab in R/R CLLActive, not recruitingNCT02970318Phase 3Results posted
- A Study of ACP-196 (Acalabrutinib) in Subjects With Relapsed/Refractory CLL and Intolerant of Ibrutinib TherapyActive, not recruitingNCT02717611Phase 2Results posted
- A Phase 1b/2, Multicenter, Open-label Study of ACP-196 in Subjects With Recurrent Glioblastoma Multiforme (GBM)Active, not recruitingNCT02586857Phase 1/2Results posted
- Study of Acalabrutinib (ACP-196) Versus Ibrutinib in Previously Treated Participants With High Risk Chronic Lymphocytic Leukemia (CLL)Active, not recruitingNCT02477696Phase 3Results posted
- Acalabrutinib, Obinutuzumab and Chlorambucil in Treatment naïve CLLCompletedNCT02475681Phase 3Results posted
- ACP-196 (Acalabrutinib) in Combination With Pembrolizumab, for Treatment of Hematologic MalignanciesCompletedNCT02362035Phase 1/2Results posted
- Acalabrutinib in Patients With Relapsed/Refractory and Treatment naïve Deletion 17p CLL/SLLCompletedNCT02337829Phase 2Results posted
- ACP-196 (Acalabrutinib), a Novel Bruton Tyrosine Kinase (BTK) Inhibitor, for Treatment of Chronic Lymphocytic Leukemia, Richter's Syndrome or Prolymphocytic LeukemiaActive, not recruitingNCT02029443Phase 1/2Results posted
- Phase 1/2a Dose Escalation Study in Participants With CLL, SLL, or NHLCompletedNCT01994382Phase 1/2Results posted
- A Phase 2, Multicenter, Open-label Study of MEDI-551 in Adults With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)CompletedNCT01466153Phase 2Results posted
- Safety Study of CAT-8015 to Treat Advanced B-cell Non-Hodgkin Lymphoma and Chronic Lymphocytic Leukemia (NHL or CLL)CompletedNCT01030536Phase 1/2Results posted
- Safety and Dose Ranging Study of Samalizumab to Treat Relapsing or Refractory CLL or MMTerminatedNCT00648739Phase 1/2Results posted
- A Phase I, Multicenter, Dose Escalation Study of CAT-8015 in Participants With Chronic LeukemiaTerminatedNCT00587457Phase 1Results posted
- A Study to Investigate the Sequencing Strategy of Pirtobrutinib After Disease Progression on First-line Acalabrutinib Treatment for Adult Participants With Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaWithdrawnNCT06839872Phase 2
- Acalabrutinib Real World Italian obSErvational Study -ARISEActive, not recruitingNCT06205498
- REAl-world Outcomes in CHronic Lymphocytic Leukemia Patients Receiving Acalabrutinib in RomaniaActive, not recruitingNCT06170671
- Calquence CLL 1L Japan PMS _ Japan Post-Marketing Surveillance (PMS) StudyCompletedNCT05665374
- National Acalabrutinib Observational StudyActive, not recruitingNCT05437250
- CLL Therapy Approaches in RussiaActive, not recruitingNCT05140369
- A Study of Acalabrutinib Plus Venetoclax Versus Venetoclax Plus Obinutuzumab in Previously Untreated Chronic Lymphocytic Leukemia or Small Lymphocytic LymphomaActive, not recruitingNCT05057494Phase 3
- Study to Understand Clinical Characteristics, Treatment Pathway in Chronic Lymphocytic LeukemiaCompletedNCT04964908
- MEOI and HRQoL in CLL Patients Treated With BTKisCompletedNCT04938141
- Calquence CLL rr Japan PMS_Japan Post-Marketing Surveillance (PMS) Study - All Patient InvestigationCompletedNCT04872621
- Expanded Access Program for Participants Who Completed Study 13-601 and Continue to Clinically Benefit From CerdulatinibNo longer availableNCT04757259
- ALICIA (Acalabrutinib in CLL Therapy)CompletedNCT04746950
- Study of Acalabrutinib (ACP-196) in Combination With Venetoclax (ABT-199), With and Without Obinutuzumab (GA101) Versus Chemoimmunotherapy for Previously Untreated CLLActive, not recruitingNCT03836261Phase 3
- A Study of AZD6738 and Acalabrutinib in Subjects With Relapsed or Refractory Chronic Lymphocytic Leukemia (CLL)Active, not recruitingNCT03328273Phase 1
- Study to Assess Safety, Tolerability, Pharmacokinetics and Antitumor Activity of AZD4573 in Relapsed/Refractory Haematological MalignanciesCompletedNCT03263637Phase 1
- Acalabrutinib in Combination With Anti-CD20 and Venetoclax in Relapsed/Refractory or Untreated CLL/SLL/PLLCompletedNCT02296918Phase 1
- Acalabrutinib in Combination With ACP-319, for Treatment of Chronic Lymphocytic LeukemiaActive, not recruitingNCT02157324Phase 1
- A Study to Evaluate the Safety, Tolerability, and Antitumor Activity of Continuous Intravenous Infusion of MEDI-538 in Adults With B-Cell Chronic Lymphocytic Leukemia (CLL)WithdrawnNCT00676871Phase 1/2
- BL22 Immunotoxin in Treating Patients With Refractory Chronic Lymphocytic Leukemia, Prolymphocytic Leukemia, or Non-Hodgkin's LymphomaCompletedNCT00126646Phase 1